US Melanoma Market Share And Trends Analysis By Type (Superficial Spreading, Nodular, Lentigo Maglina, Acral Lentigious And Others); Gender (Male And Female); Treatment (Immunotherapy, Biologic Therapy, Radiation Therapy, Chemotherapy, Surgery And Others); Diagnosis (Abcde, Ugly Duckling, Biopsy And Others), End Users (Hospitals, Pharmaceutical Companies, Research Centers, Clinics, Laboratories) - Forecast Till 2032

US Melanoma Market Overview

The US melanoma market is anticipated to reach USD 5.73 Billion, at a 10.8% CAGR during the forecast period 2022-2032.

Melanoma is a type of cancer that develops from pigment containing cells known as melanocytes. It is the most dangerous type of skin cancer. Sometimes they develop from moles showing significant change in color.

Other changes include an increase in size, itchiness, irregular edges, or skin breakdown. Exposure to ultra violet light in people with low pigment levels is a risk factor. The tumor can be either malignant or benign.

Types of melanoma include superficial spreading melanoma, nodular melanoma, lentigo maglina melanoma, acral lentigious melanoma and others. About 98% of melanoma is localized in the US. Skin cancer is one of the most common cancers in the US.

Treatment options for melanoma include biologic therapy, immune therapy, radiation therapy, chemotherapy and surgery. Ultra violet exposure is a known risk factor of melanoma. Superficial spreading melanoma affects a large number of people in the US.

The disease is more common in men than women.

US Melanoma Market Segment Insights

US melanoma market has been segmented on the basis of type including superficial spreading, nodular, lentigo maglina, acral lentigious and others. Segmentation also includes gender male and female.

Treatment segmentation includes immunotherapy, biologic therapy, radiation therapy, chemotherapy, surgery and others. Diagnosis segmentation covers ABCDE, ugly duckling, biopsy, and others. End users include hospitals, pharmaceutical companies, research centers, clinics, and laboratories.

Regional Analysis of Melanoma Market

Melanoma market in the US is divided into states comprising Georgia, New Jersey, North Carolina, New York, Florida, Illinois, Ohio, Pennsylvania, Texas, Washington, California, Virginia and Rest of US.

California accounts for the largest market for melanoma in US followed by Florida and Ohio. California and Florida are key regions for melanoma market. A large number of melanoma cases are found in this region.

New York is the third largest market after Florida. According to American Society of Dermatology, the prevalence of melanoma is gradually increasing, and this spreads across the body. The number of skin cancer patients is growing steadily in Florida and Texas.

This is due to their exposure to ultraviolet rays and extensive use of tanning beds in these regions. Technological advancement in the field of treatment and diagnosis of melanoma in the US also drives this market. The Food and Drug Administration (FDA) classifies tanning beds as "moderate risk" devices.

Key Players for Melanoma Market

Some of the Key Players in US melanoma market are:

• Amgen, Inc.


• Bristol-Myers Squibb


• Eisai Co. Ltd.


• F. Hoffmann-La Roche Ltd.


• Genentech Inc.


• Janssen Biotech, Inc.


• Novartis International AG


• Pfizer


• Vical


• Ziopharm

The report for US melanoma market of Market Research Future comprises extensive primary research along with detailed analysis of qualitative as well as quantitative aspects by various industry experts.

This includes key opinion leaders to gain deeper insight into the market and industry performance. The report gives a clear picture of the current US melanoma market scenario.

This includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the US melanoma market. The report provides detailed information and strategies of the top key players in the industry.

The report also gives a broad study of the different markets segments and regions.

Study Objectives of Melanoma Market

• To provide detailed analysis of the market structure along with forecast for the next six years of various segments and sub-segments of the US melanoma market.


• To provide insights about factors affecting the US melanoma market growth.


• To analyze the melanoma market based on various factors price analysis, supply chain analysis, Porters Five Force analysis etc.


• To provide historical and forecast revenue of the market segments and sub-segments with respect to the US.


• To provide country level analysis of the market with respect to the current US melanoma market size and future prospective.


• To provide country level analysis of the market for segments by type, by end users and its sub-segments.


• To provide overview of key players and their strategic profiling in the US melanoma market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the US melanoma market.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the US melanoma market.

Intended Audience

• Hospitals


• Pharmaceutical companies


• Research and development (R&D) companies


• Academic medical institutes and universities


• Melanoma drug manufactures


• Melanoma drug suppliers

 

Attribute/Metric	Details
Market Size 2032	USD 5.73 Billion
Compound Annual Growth Rate (CAGR)	10.8% (2022-2032)
Base Year	2022
Forecast Period	2023-2032
Historical Data	2019 - 2022
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Gender, Treatment, Diagnosis, End Users
Geographies Covered	South Africa, Egypt, Nigeria, Morocco and Algeria
Key Vendors	Amgen, Inc., Bristol-Myers Squibb, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech Inc. Janssen Biotech, Inc., and Novartis International AG. Pfizer, Vical and Ziopharm.
Key Market Drivers	Technological advancement in the field of treatment and diagnosis of melanoma in the US also drives this market.